Why did Amgen need to amend its equity plans?

Amgen amended its equity incentive plans and award agreements to comply with new IRS regulations under Code Section 409A, which govern nonqualified deferred compensation. These changes were necessary to ensure that awards granted under these plans are either exempt from these regulations or comply with them, thus avoiding potential tax penalties for both the company and its employees.

What is Code Section 409A and why is it important?

Code Section 409A is an IRS regulation that addresses rules for deferred compensation plans. It imposes strict guidelines on when and how deferred compensation can be paid. Failure to comply with Section 409A can result in significant tax penalties for the recipient, including immediate taxation of all deferred compensation, plus an additional 20% tax and potential interest charges. Amgen's amendments were designed to prevent these penalties.

How does the amendment to the Credit Agreement affect Amgen?

The amendment to the Credit Agreement extends the maturity date of Amgen's credit facility from July 16, 2009, to November 30, 2010. This provides the company with an extended period to repay its borrowings under that agreement, offering greater financial flexibility and potentially reducing refinancing risk in the medium term.

Are these changes expected to impact Amgen's stock price or financial performance directly?

These amendments are primarily procedural and regulatory-driven, focusing on compliance and financial structure. They are not expected to have a direct, immediate impact on Amgen's stock price or its day-to-day financial performance. However, ensuring compliance with tax regulations and maintaining a flexible credit structure are important for long-term financial health and investor confidence.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) filed an 8-K on December 7, 2005, reporting on significant corporate actions approved by its Board of Directors and Compensation Committee in early December 2005. The primary focus of this filing is the amendment and restatement of several key equity incentive plans and award agreements, including the 1991, 1997 (Acquired), and 1999 Equity Incentive Plans, the Performance Award Program, and the Director Equity Incentive Program. These changes were made to ensure compliance with new IRS regulations concerning deferred compensation under Code Section 409A, aiming to maintain tax-exempt status for certain awards and avoid penalties. Additionally, Amgen announced an amendment to its Credit Agreement, extending the maturity date from July 16, 2009, to November 30, 2010. This amendment provides Amgen with extended financial flexibility. Investors should note that while these actions are primarily procedural and regulatory-driven, they are crucial for the proper functioning and administration of Amgen's executive and director compensation structures and its overall debt management.

Key Highlights

1Amgen amended and restated its equity incentive plans (1991, 1997, 1999 Plans) and Performance Award Program to comply with new IRS Code Section 409A regulations on deferred compensation.
2The amendments aim to ensure that stock options, restricted stock units, and performance awards are structured to be exempt from or compliant with Code Section 409A, thereby avoiding potential tax penalties.
3Key changes include revised grant price language for stock options, specific timing for payments of restricted stock units and performance awards to qualify for short-term deferral exemptions, and provisions for future amendments to maintain compliance.
4Amgen also amended and restated its Director Equity Incentive Program and related award agreements for similar compliance with Code Section 409A.
5The company's Credit Agreement, originally maturing in July 2009, has been amended to extend the maturity date to November 30, 2010.
6These amendments to compensation plans and the credit agreement were approved by the Compensation Committee and/or the Board of Directors between December 5th and December 6th, 2005.
7The filing includes numerous exhibits detailing the specific amended and restated plans and agreements.

AMGEN INC 8-K Report, Material Agreement (Dec 8, 2005)

Summary

Key Highlights

Frequently Asked Questions